JP4656939B2 - フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター - Google Patents

フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター Download PDF

Info

Publication number
JP4656939B2
JP4656939B2 JP2004522648A JP2004522648A JP4656939B2 JP 4656939 B2 JP4656939 B2 JP 4656939B2 JP 2004522648 A JP2004522648 A JP 2004522648A JP 2004522648 A JP2004522648 A JP 2004522648A JP 4656939 B2 JP4656939 B2 JP 4656939B2
Authority
JP
Japan
Prior art keywords
mmol
added
dichloromethane
phenyl
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004522648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538089A (ja
JP2005538089A5 (https=
Inventor
ロバート・ディーン・ダリー
ジェフリー・アラン・ドッジ
スコット・アラン・フランク
スコット・アラン・ジョーンズ
ティモシー・アラン・シェパード
オーウェン・ブレンダン・ウォレス
キン・チュウ・フォン
コンラッド・ウィルソン・ハメル
ジョージ・サル・ルイス
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2005538089A publication Critical patent/JP2005538089A/ja
Publication of JP2005538089A5 publication Critical patent/JP2005538089A5/ja
Application granted granted Critical
Publication of JP4656939B2 publication Critical patent/JP4656939B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2004522648A 2002-07-22 2003-07-16 フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター Expired - Fee Related JP4656939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39786902P 2002-07-22 2002-07-22
US45023303P 2003-02-25 2003-02-25
PCT/IB2003/003349 WO2004009086A1 (en) 2002-07-22 2003-07-16 Selective estrogen receptor modulators containing a phenylsulfonyl group

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010109009A Division JP5220800B2 (ja) 2002-07-22 2010-05-11 フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター

Publications (3)

Publication Number Publication Date
JP2005538089A JP2005538089A (ja) 2005-12-15
JP2005538089A5 JP2005538089A5 (https=) 2007-08-16
JP4656939B2 true JP4656939B2 (ja) 2011-03-23

Family

ID=30773044

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004522648A Expired - Fee Related JP4656939B2 (ja) 2002-07-22 2003-07-16 フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
JP2010109009A Expired - Fee Related JP5220800B2 (ja) 2002-07-22 2010-05-11 フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010109009A Expired - Fee Related JP5220800B2 (ja) 2002-07-22 2010-05-11 フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター

Country Status (24)

Country Link
US (2) US7399867B2 (https=)
EP (1) EP1530470B9 (https=)
JP (2) JP4656939B2 (https=)
CN (1) CN1668303B (https=)
AT (1) ATE433322T1 (https=)
AU (1) AU2003253129B2 (https=)
BR (1) BR0312675A (https=)
CA (1) CA2490580C (https=)
CO (1) CO5680445A2 (https=)
CR (1) CR7657A (https=)
DE (1) DE60327931D1 (https=)
EA (1) EA008024B1 (https=)
EC (1) ECSP055549A (https=)
ES (1) ES2326593T3 (https=)
HR (1) HRP20041233A2 (https=)
IL (1) IL165745A0 (https=)
MX (1) MXPA05000898A (https=)
MY (1) MY141879A (https=)
NO (1) NO20050832L (https=)
NZ (1) NZ537138A (https=)
PE (1) PE20040678A1 (https=)
PL (1) PL374845A1 (https=)
TW (1) TWI314860B (https=)
WO (1) WO2004009086A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195820A (ja) * 2002-07-22 2010-09-09 Eli Lilly & Co フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20050675A2 (en) * 2003-02-25 2005-10-31 Eli Lilly And Company Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
CN100348192C (zh) * 2003-02-25 2007-11-14 伊莱利利公司 晶状的非溶剂化1－(4－(2－哌啶基乙氧基)苯氧基)－2－(4－甲磺酰基苯基)－6－羟基萘盐酸化物
EP1709021B1 (en) * 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
ATE448215T1 (de) * 2004-01-22 2009-11-15 Lilly Co Eli Selektive östrogen-rezeptor-modulatoren
CN1910167B (zh) * 2004-01-22 2011-08-10 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
EP1713770A1 (en) * 2004-01-29 2006-10-25 Eli Lilly And Company Selective estrogen receptor modulators
CA2571309A1 (en) * 2004-06-22 2006-01-05 Smithkline Beecham Corporation Chemical compounds
CA2617146A1 (en) * 2005-07-29 2007-02-08 Eli Lilly And Company Crystalline non-solvated methanesulfonic acid salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene
EA020742B1 (ru) * 2008-09-29 2015-01-30 Эли Лилли Энд Компани Селективный модулятор рецепторов эстрогена
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
BR112015018882B1 (pt) 2013-02-19 2021-09-14 Novartis Ag Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
WO2020182649A1 (en) 2019-03-08 2020-09-17 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
BR112021018501A2 (pt) 2019-03-20 2021-11-30 Syngenta Crop Protection Ag Compostos de azolamida ativos em termos pesticidas
CN113597426A (zh) 2019-03-22 2021-11-02 先正达农作物保护股份公司 N-[1-(5-溴-2-嘧啶-2-基-1,2,4-三唑-3-基)乙基]-2-环丙基-6-(三氟甲基)吡啶-4-甲酰胺衍生物及相关的化合物作为杀昆虫剂
TWI853009B (zh) 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物
JP7611848B2 (ja) 2019-04-05 2025-01-10 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性なジアジン－アミド化合物
BR112022003375A2 (pt) 2019-08-23 2022-05-17 Syngenta Crop Protection Ag Compostos de pirazina-amida pesticidamente ativos
CN110526881B (zh) * 2019-08-27 2020-09-22 河南省锐达医药科技有限公司 一种萘胺类化合物及其生物学可接受的盐，其制备方法和应用
JP2023515979A (ja) 2020-02-27 2023-04-17 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性なジアジン－ビスアミド化合物
WO2022237904A1 (zh) * 2021-05-14 2022-11-17 江苏亚虹医药科技股份有限公司 一种含萘环的化合物、含其的药物组合物及其应用
JP2024524883A (ja) 2021-06-09 2024-07-09 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性なジアジン－アミド化合物
US20240208950A1 (en) * 2021-07-07 2024-06-27 South Dakota Board Of Regents Compositions and methods for treatment of cervical and ovarian cancer
CN119768396A (zh) 2022-08-25 2025-04-04 赛诺菲 新颖的取代的苯并噻吩-6-羧酸衍生物、其制备方法及其治疗用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
CA2135160A1 (en) 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Indole derivative
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6399634B1 (en) * 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
UA44710C2 (uk) 1995-02-28 2002-03-15 Елі Ліллі Енд Компані Похідні бензотіофену, спосіб їх одержання (варіанти), проміжні сполуки, фармацевтична композиція
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
CA2236007A1 (en) * 1995-10-31 1997-07-17 Gerald Floyd Smith Antithrombotic diamines
PT791591E (pt) * 1996-02-22 2001-12-28 Lilly Co Eli Benzotiofenos, formulacoes que os contem e metodos
DE69707189T2 (de) 1996-04-19 2002-06-20 American Home Products Corp., Madison Östrogene Verbindungen
CA2213810C (en) 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
ID19392A (id) 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2214070C (en) 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
CA2213814A1 (en) 1996-08-29 1998-02-28 Henry Uhlman Bryant Naphthalene compounds, intermediates, formulations, and methods
CA2217810A1 (en) 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
CA2218756A1 (en) 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
ATE433322T1 (de) * 2002-07-22 2009-06-15 Lilly Co Eli Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195820A (ja) * 2002-07-22 2010-09-09 Eli Lilly & Co フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター

Also Published As

Publication number Publication date
JP2010195820A (ja) 2010-09-09
EP1530470B9 (en) 2010-04-07
CA2490580C (en) 2012-12-11
MY141879A (en) 2010-07-16
TW200414901A (en) 2004-08-16
US20080214612A1 (en) 2008-09-04
EP1530470A1 (en) 2005-05-18
ES2326593T3 (es) 2009-10-15
AU2003253129A1 (en) 2004-02-09
DE60327931D1 (de) 2009-07-23
JP2005538089A (ja) 2005-12-15
BR0312675A (pt) 2005-05-03
PL374845A1 (en) 2005-11-14
CR7657A (es) 2005-07-13
CN1668303B (zh) 2010-10-27
CO5680445A2 (es) 2006-09-29
PE20040678A1 (es) 2004-10-06
NZ537138A (en) 2007-11-30
EA200500248A1 (ru) 2005-06-30
WO2004009086A1 (en) 2004-01-29
CA2490580A1 (en) 2004-01-29
AU2003253129B2 (en) 2008-12-11
US7585977B2 (en) 2009-09-08
EA008024B1 (ru) 2007-02-27
EP1530470B1 (en) 2009-06-10
US7399867B2 (en) 2008-07-15
ECSP055549A (es) 2005-03-10
MXPA05000898A (es) 2005-05-16
IL165745A0 (en) 2006-01-15
US20060183736A1 (en) 2006-08-17
TWI314860B (en) 2009-09-21
JP5220800B2 (ja) 2013-06-26
CN1668303A (zh) 2005-09-14
HRP20041233A2 (en) 2005-02-28
ATE433322T1 (de) 2009-06-15
NO20050832L (no) 2005-02-16
HK1078003A1 (en) 2006-03-03

Similar Documents

Publication Publication Date Title
JP5220800B2 (ja) フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
JPH09183776A (ja) ベンゾチオフェン化合物、中間体、組成物および方法
CA2213810C (en) Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
US5843965A (en) Benzo B! thiophene compounds, intermediates, processes, compositions, and methods
US6133458A (en) Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
US5834488A (en) Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
US7375229B2 (en) Dihydro-dibenzo[B,E]oxepine based selective estrogen receptor modulators, compositions and methods
EP1782810A2 (en) Selective estrogen receptor modulators containing a phenylsulfonyl group
KR20050019912A (ko) 페닐술포닐기를 함유하는 선택적 에스트로겐 수용체 조절제
HK1078003B (en) Selective estrogen receptor modulators containing a phenylsulfonyl group
EP1551822B1 (en) Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them
EP1709023A1 (en) Selective estrogen receptor modulators
EP0832891B1 (en) Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070608

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100511

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees